Functional Aspects of Fibrin Structure Alterations by Tranexamic Acid in the Inhibition of Fibrinolysis
Biomolecules · 08.05.2026 · 16 (5) · 696
DOI: 10.3390/biom16050696 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biomolecules, online erschienen am 08.05.2026. Verfasst von Kata Balog Virag und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry, Institute of Biochemistry and Molecular Biology, Semmelweis University, 1094 Budapest, Hungary. Hauptthemen laut MEDLINE: Tranexamic Acid, Fibrinolysis, Fibrin, Antifibrinolytic Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: EU's Horizon 2020 research and innovation program, National Research, Development and Innovation Office, Semmelweis University.
Abstract (Originalsprache)
Background
Tranexamic acid (TXA) is a synthetic lysine analog widely used as an antifibrinolytic agent. Large randomized trials have demonstrated life-saving benefits when TXA is administered early in acute hemorrhage, but results regarding prophylactic administration have been conflicting, and several trials have not shown improved clinical outcomes. The mechanisms underlying this discrepancy remain incompletely understood.
Objectives
To investigate the molecular and structural mechanisms that determine TXA efficacy in purified fibrin clots under conditions mimicking therapeutic versus prophylactic administration.
Methods
We examined fibrinolysis induced by tissue plasminogen activator (tPA) in vitro using confocal microscopy, viscoelastic testing (ClotPro), turbidimetry, and plasmin generation assays at physiologically and therapeutically relevant concentrations of plasminogen and TXA. Scanning electron microscopy (SEM) was employed to assess fibrin structure.
Results
When TXA was incorporated into fibrin clots before the addition of tPA, physiological plasminogen concentrations (2.5 µM) reversed the antifibrinolytic effect, resulting in paradoxical acceleration of lysis. By contrast, when clotting and fibrinolysis occurred simultaneously in the presence of TXA and tPA, TXA consistently prolonged lysis time irrespective of plasminogen concentration. SEM demonstrated that TXA, even at concentrations as low as 16 µM, doubled the top-quartile values of the fibrin fiber diameter, altering susceptibility to plasmin-mediated degradation without accelerating plasminogen activation.
Conclusions
TXA efficacy is determined not only by dose but also by timing and the plasminogen availability in the clot microenvironment. These findings provide mechanistic insight into the failure of prophylactic TXA administration and highlight the importance of context in optimizing its clinical use.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biochemistry, Institute of Biochemistry and Molecular Biology, Semmelweis University, 1094 Budapest, Hungary.
- HCEMM-SU Thrombosis and Hemostasis Research Group, Department of Biochemistry, Semmelweis University, 1094 Budapest, Hungary.
- Plasma Chemistry Research Group, Institute of Materials and Environmental Chemistry, Research Centre for Natural Sciences, 1117 Budapest, Hungary.
- Department of Mechatronics, Faculty of Engineering, Nikola Vaptsarov Naval Academy, 9002 Varna, Bulgaria.
- Department of Computer Science, Varna Free University "Chernorizets Hrabar", 9007 Varna, Bulgaria.
- Australian Maritime College, University of Tasmania, Launceston, TAS 7250, Australia.
ORCID-Profile: Kata Balog Virag, Barbara Baráth, Kristóf Molnár, Petra Csikós, Alexandra Raska, László Szabó, Natalia Nikolova, Kiril Tenekedjiev, Krasimir Kolev, Nikolett Wohner
Förderung
- EU's Horizon 2020 research and innovation program
- National Research, Development and Innovation Office
- Semmelweis University
- CELSA
- University of Tasmania/Australian Maritime College
- EU’s Horizon 2020 research and innovation program
- Hungarian National Research, Development and Innovation Office
- Central Europe Leuven Strategic Alliance CELSA
Zitieren
APA
Balog Virag, K., Baráth, B., Molnár, K., Csikós, P., Raska, A., Szabó, L., Nikolova, N., Tenekedjiev, K., Kolev, K., & Wohner, N. (2026). Functional Aspects of Fibrin Structure Alterations by Tranexamic Acid in the Inhibition of Fibrinolysis. Biomolecules, 16(5), 696. https://doi.org/10.3390/biom16050696
Vancouver
Balog Virag K, Baráth B, Molnár K, Csikós P, Raska A, Szabó L, et al. Functional Aspects of Fibrin Structure Alterations by Tranexamic Acid in the Inhibition of Fibrinolysis. Biomolecules. 2026;16(5):696. doi:10.3390/biom16050696
BibTeX
@article{BalogVirag2026,
author = {Balog Virag, Kata and Baráth, Barbara and Molnár, Kristóf and Csikós, Petra and Raska, Alexandra and Szabó, László and Nikolova, Natalia and Tenekedjiev, Kiril and Kolev, Krasimir and Wohner, Nikolett},
title = {Functional Aspects of Fibrin Structure Alterations by Tranexamic Acid in the Inhibition of Fibrinolysis},
journal = {Biomolecules},
year = {2026},
volume = {16},
number = {5},
pages = {696},
doi = {10.3390/biom16050696}
}
EUVIMED